These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 22327175

  • 1. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.
    Cancer Lett; 2010 Feb 28; 288(2):251-60. PubMed ID: 19664879
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
    Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM.
    J Surg Res; 2008 May 01; 146(1):16-23. PubMed ID: 17950331
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D.
    Cancer; 2003 Oct 01; 98(7):1377-85. PubMed ID: 14508823
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.
    Molnar N, Siemann DW.
    Microvasc Res; 2012 May 01; 83(3):290-7. PubMed ID: 22387475
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
    Gardner ER, Kelly M, Springman E, Lee KJ, Li H, Moore W, Figg WD.
    Invest New Drugs; 2012 Feb 01; 30(1):90-7. PubMed ID: 20820910
    [Abstract] [Full Text] [Related]

  • 15. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M.
    Clin Cancer Res; 2013 Dec 15; 19(24):6730-40. PubMed ID: 24097868
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ.
    Urol Oncol; 2011 Dec 15; 29(4):421-9. PubMed ID: 19576799
    [Abstract] [Full Text] [Related]

  • 18. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
    Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M.
    Clin Cancer Res; 2018 Jun 15; 24(12):2749-2757. PubMed ID: 29559563
    [Abstract] [Full Text] [Related]

  • 19. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.
    Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloterä H, Tammela T, Benjamin LE, Ylä-Herttuala S, Leow CC, Koh GY, Alitalo K.
    J Natl Cancer Inst; 2012 Mar 21; 104(6):461-75. PubMed ID: 22343031
    [Abstract] [Full Text] [Related]

  • 20. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ.
    Cancer Res; 2002 May 01; 62(9):2567-75. PubMed ID: 11980651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.